Avacta Group: Shaun Chilton

Shaun Chilton

Avacta Group, a life sciences company developing oncology drugs and diagnostics, has appointed Shaun Chilton as a non-executive director.

Chilton has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. He was most recently chief executive of the formerly London-listed Clinigen Group, a global pharmaceutical and pharmaceutical services platform business. The company was sold to Triton Partners for around £1.3 billion last year.

Chilton was also non-executive chairman of C7Health, a disruptive, venture capital-backed medical technology and services business which was acquired by a strategic buyer last year.

He has also worked at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).

Dr Eliot Forster, chairman of Avacta Group said: “[Chilton] brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I’m excited to have him join the company.”

Dr Alastair Smith, chief executive of Avacta Group commented: “[Chilton] brings deep and extensive commercial experience to further strengthen the senior leadership of the group as it executes its strategy across two divisions to build a major global healthcare business working to improve people’s health and well-being through innovative oncology drugs and powerful diagnostics.”

Chilton said: “Avacta Group is building a high-value, global business that is seeking to significantly improve people’s health and wellbeing. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the board to help guide Avacta to meet its very significant potential.”

Join our mailing list

Stay up to date with all our events, awards and publications.

Information you provide us with will be kept private at all times, and will be used for communication and research purpose only.